Walgreen's WHP pilot study encourages testing for H. pylori in high-risk patients.
Executive Summary
WALGREEN's WHP H. PYLORI EDUCATION PILOT STUDY will assess cost-effectiveness of Walgreen's pharmacy benefit management subsidiary WHP Health Initiatives' approach to encourage testing for treatment of ulcers caused by Helicobacter pylori, WHP Managed Care Pharmacy Resident Mark Matusik told the Academy of Managed Care annual meeting in New Orleans May 9. WHP Health Initiatives surveyed 5,062 patients chosen from Walgreen's pharmacy database on the basis of long-term use of acid-lowering drugs. Forty-five percent of patients responded.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth